Unveiling Italy’s New Sunshine Act

October 25th, 2023

3:30 pm – 4:30 pm CET (Central European Time)
9:30 am – 10:30 am EST (Eastern Standard Time)

Register Now

Industry experts will share their insights about the new law.

About the Webinar:

On June 26, 2022, the Italian Sunshine Act n.62/2022 entered into law, its full enforceability is expected by December 2023, when the Italian Telematic Public Register “Registro pubblico Sanità trasparente” by “Ministero della Salute (Health Ministry)” for disclosures publication is launched.

While waiting for the full enforcement, companies may take advantage of this time period to prepare for the law.

Edoardo Lazzarini and Sylvia Asghar will share insights about:

  • Details of the upcoming Italian Transparency law
  • Current Status and guidance on how to prepare
  • And answer your questions

Register now and also receive access to “Italian Sunshine Reporting” resource page including web links, social media content, government and public sites, and direct links to the industry experts.


Sylvia Asghar

Edoardo Lazzarini

Edoardo Lazzarini has over 25 years of experience in the pharmaceutical industry in Italy with Merck, Takeda, Zimmer and GSK.

Most recently he oversaw the implementation of business ethics & compliance programs in for GSK (Haleon). Edoardo was awarded the “Leadership in the Advancement of Ethics” award; he was Vice Chair of the Compliance Network in MedTech Europe and member of “B20 Integrity & Compliance Taskforce”. Edoardo is deeply familiar with Farma Industria, and additionally, he teaches at a graduate college, speaks at compliance conferences, and regularly writes on compliance, anti- corruption, and Italian Sunshine Act.


Sylvia Asghar Attorney (UK)

Solicitor (Manchester, UK)
Sylvia has several years of experience in the English and Welsh judicial systems.

Sylvia has worked for UK Ministry of Justice and also in private legal practice. She is also the chief editor of LegalEZ a global Compliance Transparency Newsletter, and an expert on global pharmaceutical drug and device transparency laws.